ABBV vs AUTL · P/E 81, rev $16.99B vs rev $71.9M
AbbVie Inc (ABBV) versus Autolus Therapeutics Ltd (AUTL) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Autolus Therapeutics Ltd (AUTL) is a biotechnology company listed on US.
Latest reported ABBV revenue for 2026-06-30 was $16.99B. Net income was $3.61B. Revenue was up 13.3% from 2026-03-31 to 2026-06-30. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported AUTL revenue for 2026-06-30 was $71.9M. Net income was -$110.7M. AUTL currently screens at market cap $614.8M.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. AUTL currently screens at market cap $614.8M.
Not investment advice. Open the ABBV and AUTL stock pages for the full models.
Not investment advice.